Role of mTOR in podocyte function and diabetic nephropathy in humans and mice
Open accessThe DOI matches its Crossref record; 61 of the 62 references it cites were found in a registry or an index.
Abstract
Chronic glomerular diseases, associated with renal failure and cardiovascular morbidity, represent a major health issue. However, they remain poorly understood. Here we have reported that tightly controlled mTOR activity was crucial to maintaining glomerular podocyte function, while dysregulation of mTOR facilitated glomerular diseases. Genetic deletion of mTOR complex 1 (mTORC1) in mouse podocytes induced proteinuria and progressive glomerulosclerosis. Furthermore, simultaneous deletion of both mTORC1 and mTORC2 from mouse podocytes aggravated the glomerular lesions, revealing the importance of both mTOR complexes for podocyte homeostasis. In contrast, increased mTOR activity accompanied human diabetic nephropathy, characterized by early glomerular hypertrophy and hyperfiltration. Curtailing mTORC1 signaling in mice by genetically reducing mTORC1 copy number in podocytes prevented glomerulosclerosis and significantly ameliorated the progression of glomerular disease in diabetic nephropathy. These results demonstrate the requirement for tightly balanced mTOR activity in podocyte homeostasis and suggest that mTOR inhibition can protect podocytes and prevent progressive diabetic nephropathy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Gödel et al. [16] suggested that mTOR signaling plays a role in podocyte homeostasis.”
From A case of lipoprotein glomerulopathy with a rare apolipoprotein E isoform combined with neurofibromatosis type I (2018) · cites this paper as [16]
In the citing paper
“The decrease in activity of neurofibromin in NF1 might also be associated with LPG which is a glomerular disease, and contribute to the development of LPG as an additional factor.”
From A case of lipoprotein glomerulopathy with a rare apolipoprotein E isoform combined with neurofibromatosis type I (2018) · cites this paper as [16]
In the citing paper
“Although podocytes have high basal levels of autophagy, high mTORC1 activity is also required for these cells to maintain their function”
From Autophagy in kidney homeostasis and disease (2020) · cites this paper as [51]
In the citing paper
“However, the side effects of long-term or complete mTORC1 inhibition in kidney cells have been well-recognized, such as the early onset of proteinuria caused by specific inhibition of mTORC1 activity in podocytes in mice and the disruption of kidney tubular homeostasis caused by specific inhibition of mTORC1 activity in kidney tubular cells in mice51,80.”
From Autophagy in kidney homeostasis and disease (2020) · cites this paper as [51]
Citations
Cites
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
TOR signaling in growth and metabolism
Wullschleger, S., Loewith, R., & Hall, M. N. (2006) · Cell · doi:10.1016/j.cell.2006.01.016 · Cited by 5,787
Self-citationA global double-fluorescent Cre reporter mouse
Muzumdar, M. D., Tasic, B., Miyamichi, K., Li, L., & Luo, L. (2007) · genesis · doi:10.1002/dvg.20335 · Cited by 3,491
Watterson, K. R., Bestow, D., Gallagher, J., Hamilton, D. L., Ashford, F. B., Meakin, P. J., & Ashford, M. L. J. (2013) · Neurosignals · doi:10.1159/000334144 · Cited by 3,389
The unbiased estimation of number and sizes of arbitrary particles using the disector
Sterio, D. C. (1984) · Journal of Microscopy · doi:10.1111/j.1365-2818.1984.tb02501.x · Cited by 2,519
Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365
Laplante, M., & Sabatini, D. M. (2009) · Journal of Cell Science · doi:10.1242/jcs.051011 · Cited by 2,170
Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity
Um, S. H., Frigerio, F., Watanabe, M., Picard, F., Joaquin, M., Sticker, M., Fumagalli, S., Allegrini, P. R., Kozma, S. C., Auwerx, J., et al. (2004) · Nature · doi:10.1038/nature02866 · Cited by 1,677
VEGF Inhibition and Renal Thrombotic Microangiopathy
Eremina, V., Jefferson, J. A., Kowalewska, J., Hochster, H., Haas, M., Weisstuch, J., Richardson, C., Kopp, J. B., Kabir, M. G., Backx, P. H., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707330 · Cited by 1,504
Holz, M. K., Ballif, B. A., Gygi, S. P., & Blenis, J. (2005) · Cell · doi:10.1016/j.cell.2005.10.024 · Cited by 1,262
Research works printed but not linked: 5
- Estacio, 2001, Adv Intern Med., 46, 359
- Munivenkatappa, 2010, Histol Histopathol., 25, 189
- Weening, 1987, Am J Pathol., 129, 64
- Artacho-Perula, 1993, Lab Invest., 68, 56
- Souster, 1980, J Anat., 130, 595
Cited by
Items 101–200 of 553
Mechanisms and biological functions of autophagy in diseased and ageing kidneys
Fougeray, S., & Pallet, N. (2014) · Nature Reviews Nephrology · doi:10.1038/nrneph.2014.201 · Cited by 115
Zheng, W., Guo, J., & Liu, Z. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01079-5 · Cited by 113
Hydrogen Sulfide: Recent Progression and Perspectives for the Treatment of Diabetic Nephropathy
Sun, H., Wu, Z., Cao, L., Zhu, M., Liu, T.-T., Guo, L., Lin, Y., Nie, X.-W., & Bian, J. (2019) · Molecules · doi:10.3390/molecules24152857 · Cited by 107
Regulating Autophagy as a Therapeutic Target for Diabetic Nephropathy
Kitada, M., Ogura, Y., Monno, I., & Koya, D. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0879-y · Cited by 108
Renal Allograft Fibrosis: Biology and Therapeutic Targets
Boor, P., & Floege, J. (2015) · American Journal of Transplantation · doi:10.1111/ajt.13180 · Cited by 116
Chronic kidney disease and diabetes
Pyram, R., Kansara, A., Banerji, M. A., & Loney‐Hutchinson, L. (2011) · Maturitas · doi:10.1016/j.maturitas.2011.11.009 · Cited by 119
Podocytes maintain high basal levels of autophagy independent of mtor signaling
Bork, T., Liang, W., Yamahara, K., Lee, P., Tian, Z., Liu, S., Schell, C., Thedieck, K., Hartleben, B., Patel, K., et al. (2020) · Autophagy · doi:10.1080/15548627.2019.1705007 · Cited by 100
“this indicates an uncoupling of MTOR and autophagy in these cells [5,28].”
BackgroundMethodInfluentialSelf-citationmTOR-mediated podocyte hypertrophy regulates glomerular integrity in mice and humans
Puelles, V. G., van der Wolde, J. W., Wanner, N., Scheppach, M. W., Cullen‐McEwen, L. A., Bork, T., Lindenmeyer, M. T., Gernhold, L., Wong, M. N., Braun, F., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.99271 · Cited by 102
“mTOR signaling is essential during kidney development and for kidney growth during physiological body growth (18).”
BackgroundSelf-citationSPAG5‐AS1 inhibited autophagy and aggravated apoptosis of podocytes via SPAG5/AKT/mTOR pathway
Xu, J., Deng, Y., Wang, Y., Sun, X., Chen, S., & Fu, G. (2020) · Cell Proliferation · doi:10.1111/cpr.12738 · Cited by 100
Exosomes derived from mesenchymal stem cells in diabetes and diabetic complications
Jiao, Y., Chen, K.-X., Tang, X., Tang, Y., Yang, H., Yin, Y., & Li, C. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06659-w · Cited by 109
“The activation of mTOR was crucial to the preservation of glomerular podocyte function, as well as the occurrence of glomerular and tubular cell hypertrophy and podocytes damage, on the contrary, mTOR inhibition might preserve podocytes and prevent the progression of diabetic nephropathy [70].”
BackgroundLoss of TIMP3 underlies diabetic nephropathy via FoxO1/STAT1 interplay
Fiorentino, L., Cavalera, M., Menini, S., Marchetti, V., Mavilio, M., Fabrizi, M., Conserva, F., Casagrande, V., Menghini, R., Pontrelli, P., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201201475 · Cited by 98
“…of diabetic nephropathy through intracellular stress induced-autophagy (such as AMPK and mTOR activity, hypoxia and ER stress; Fogo, 2011; Godel et al, 2011; He et al, 2010; Inoki et al, 2011; Kume et al, 2010, 2012; Nath, 2010) were not affected in our models (Supporting Information Fig…”
Kitada, M., Ogura, Y., Suzuki, T., Sen, S., Lee, S. M., Kanasaki, K., Kume, S., & Koya, D. (2016) · Diabetologia · doi:10.1007/s00125-016-3925-4 · Cited by 97
Rictor/mTORC2 signaling mediates TGFβ1-induced fibroblast activation and kidney fibrosis
Li, J., Ren, J., Liu, X., Jiang, L., He, W., Yuan, W., Yang, J., & Dai, C. (2015) · Kidney International · doi:10.1038/ki.2015.119 · Cited by 93
Signaling pathways and intervention for therapy of type 2 diabetes mellitus
Cao, R. Y., Tian, H., Zhang, Y., Liu, G., Xu, H., Rao, G., Tian, Y., & Fu, X. (2023) · MedComm · doi:10.1002/mco2.283 · Cited by 109
Zhao, X., Chen, Y., Tan, X., Zhang, L., Zhang, H., Li, Z., Liu, S., Li, R., Lin, T., Liao, R., et al. (2018) · The Journal of Pathology · doi:10.1002/path.5077 · Cited by 93
“Consistent with previous studies [6], mTOR was hyperactivated in podocytes from patients with DN compared with the control (Figure 4A).”
BackgroundResultSelf-citationLee, H. W., Khan, S. Q., Khaliqdina, S. J., Altintas, M. M., Grahammer, F., Zhao, J. L., Koh, K. H., Tardi, N. J., Faridi, M. H., Geraghty, T., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.753822 · Cited by 97
“In another study, miR-146a levels were reduced in the retina, kidney, and heart of streptozotocin (STZ)-induced diabetic rats.”
BackgroundMethodInfluentialSelf-citationComing full circle in diabetes mellitus: from complications to initiation
Harcourt, B. E., Penfold, S. A., & Forbes, J. M. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.236 · Cited by 97
DEPTOR at the Nexus of Cancer, Metabolism, and Immunity
Caron, A., Briscoe, D. M., Richard, D., & Laplante, M. (2018) · Physiological Reviews · doi:10.1152/physrev.00064.2017 · Cited by 94
Podocyte-targeted therapies — progress and future directions
Meliambro, K. A., He, C., & Campbell, K. N. (2024) · Nature Reviews Nephrology · doi:10.1038/s41581-024-00843-z · Cited by 93
“In addition, mTOR signalling regulates podocyte cytoarchitecture and function 87 .”
Role of pyruvate kinase M2-mediated metabolic reprogramming during podocyte differentiation
Yuan, Q., Miao, J., Yang, Q., Fang, L., Fang, Y., Ding, H., Zhou, Y., Jiang, L., Dai, C., Zen, K., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2481-5 · Cited by 95
The Role of Autophagy in the Pathogenesis of Diabetic Nephropathy
Yamahara, K., Yasuda, M., Kume, S., Koya, D., Maegawa, H., & Uzu, T. (2013) · Journal of Diabetes Research · doi:10.1155/2013/193757 · Cited by 85
“Interestingly, in podocytes of diabetic mice and patients, mTORC1 is highly activated and may be involved in the mechanisms of diabetes-related autophagy inhibition in podocytes [63].”
BackgroundSalatto, C. T., Miller, R., Cameron, K. O., Cokorinos, E., Reyes, A. R., Ward, J., Calabrese, M. F., Kurumbail, R. G., Rajamohan, F., Kalgutkar, A. S. S., et al. (2017) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.237925 · Cited by 85
“Glomerular mechanistic target of rapamycin (mTOR) activity is an established driver of podocyte hypertrophy and compromised filtration barrier (Gödel et al., 2011; Inoki et al., 2011; Inoki and Huber, 2012; Eid et al., 2013).”
BackgroundMok, K., Mruk, D. D., & Cheng, C. Y. (2013) · International review of cytology · doi:10.1016/b978-0-12-407704-1.00006-3 · Cited by 90
Podocyte energy metabolism and glomerular diseases
Imasawa, T., & Rossignol, R. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.06.013 · Cited by 90
Kingswood, J. C., Bissler, J. J., Budde, K., Hulbert, J. C., Guay‐Woodford, L. M., Sampson, J. R., Sauter, M., Cox, J., Patel, U., Elmslie, F., et al. (2016) · The Nephron journals/Nephron journals · doi:10.1159/000448293 · Cited by 87
Chen, J., Chen, M. X., Fogo, A. B., Harris, R. C., & Chen, J.-K. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012010101 · Cited by 82
Kravets, I., & Mallipattu, S. K. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa029 · Cited by 91
“The molecular event responsible for this hypertrophy is activation of mammalian target of rapamycin signaling, a process responsible for cellular development and regeneration [54, 55].”
BackgroundInhibition of insulin/IGF‐1 receptor signaling protects from mitochondria‐mediated kidney failure
Ising, C., Koehler, S., Brähler, S., Merkwirth, C., Höhne, M., Baris, O. R., Hagmann, H., Kann, M., Fabretti, F., Dafinger, C., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404916 · Cited by 87
Rapamycin promotes podocyte autophagy and ameliorates renal injury in diabetic mice
Xiao, T., Guan, X., Nie, L., Wang, S., Sun, L., He, T., Huang, Y., Zhang, J., Yang, K., Wang, J., et al. (2014) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-014-2090-7 · Cited by 85
Huang, C., Lin, M. Z., Cheng, D., Braet, F., Pollock, C. A., & Chen, X. (2016) · Scientific Reports · doi:10.1038/srep23884 · Cited by 81
Expression of mTOR in normal and pathological conditions
Marques-Ramos, A., & Cervantes, R. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01820-z · Cited by 83
“nephropathy Elevated mTOR mRNA levels [106]”
BackgroundTargeting mTOR Signaling Can Prevent the Progression of FSGS
Zschiedrich, S., Bork, T., Liang, W., Wanner, N., Eulenbruch, K., Munder, S., Hartleben, B., Kretz, O., Gerber, S., Simons, M., et al. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016050519 · Cited by 76
Self-citationTwenty years after ACEIs and ARBs: emerging treatment strategies for diabetic nephropathy
Johnson, S. A., & Spurney, R. F. (2015) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00266.2015 · Cited by 79
“Embryonic deletion of the mTORC1 component Raptor in mouse podocytes causes robust albuminuria and glomerulosclerosis (49).”
BackgroundInfluentialCell Apoptosis and Autophagy in Renal Fibrosis
Zhao, X., Livingston, M. J., Liang, X., & Dong, Z. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-8871-2_28 · Cited by 78
Targeting immune cell metabolism in kidney diseases
Basso, P. J., Andrade‐Oliveira, V., & Câmara, N. O. S. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-021-00413-7 · Cited by 80
Fasting and rapamycin: diabetes versus benevolent glucose intolerance
Blagosklonny, M. V. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-1822-8 · Cited by 74
In vivo evidence for mTORC2-mediated actin cytoskeleton rearrangement in neurons
Angliker, N., & Rüegg, M. A. (2013) · BioArchitecture · doi:10.4161/bioa.26497 · Cited by 72
Self-citationPodocyte EGFR Inhibits Autophagy Through Upregulation of Rubicon in Type 2 Diabetic Nephropathy
Li, Y., Pan, Y., Cao, S., Sasaki, K., Wang, Y., Niu, A., Fan, X., Wang, S., Zhang, M., & Harris, R. C. (2020) · Diabetes · doi:10.2337/db20-0660 · Cited by 75
“mTOR activity increases in podocytes in diabetic mice and correlates with increased endoplasmic reticulum stress and progressive glomerulosclerosis (8).”
BackgroundPodocyte loss involves MDM2 ‐driven mitotic catastrophe
Mulay, S. R., Thomasová, D., Ryu, M., Kulkarni, O. P., Migliorini, A., Bruns, H., Gröbmayr, R., Lazzeri, E., Lasagni, L., Liapis, H., et al. (2013) · The Journal of Pathology · doi:10.1002/path.4193 · Cited by 79
“It is likely that podocyte MDM2 has a similar role to mTOR, eg in diabetic glomerulosclerosis [62,63].”
BackgroundmTORC2 Signaling Regulates Nox4-Induced Podocyte Depletion in Diabetes
Eid, S., Boutary, S. S., Braysh, K., Sabra, R., Massaad, C., Hamdy, A., Rashid, A., Moodad, S., Block, K. L., Gorin, Y. C., et al. (2016) · Antioxidants and Redox Signaling · doi:10.1089/ars.2015.6562 · Cited by 74
“Moreover, activation of the mTORC1 in this system by inhibiting an upstream negative regulator hamartin (TSC1) recapitulated many features of DN, including podocyte loss, GBM thickening, mesangial expansion, and proteinuria in nondiabetic young and adult mice (26, 30, 47, 52).”
BackgroundInfluentialPodocytes, Signaling Pathways, and Vascular Factors in Diabetic Kidney Disease
Brosius, F. C., & Coward, R. J. (2014) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2014.03.011 · Cited by 74
“Although these studies indicate that targeting mTORC1 for therapy of DKD is attractive, the necessity of maintaining mTOR activity at a normal level was underlined by the finding that elimination of raptor expression in podocytes resulted in significant proteinuria.(41) These studies have clearly shown that modulation…”
Fogo, A. B. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57935 · Cited by 74
Jinks, R. N., Puffenberger, E. G., Baple, E., Harding, B., Crino, P., Fogo, A. B., Wenger, O., Xin, B., Koehler, A. E., McGlincy, M. H., et al. (2015) · Brain · doi:10.1093/brain/awv153 · Cited by 69
“…determinant of human cortical growth and organization (Orlova and Crino, 2010; Cloetta et al., 2013; Lim and Crino, 2013; Tsai et al., 2014), also influences podocyte shape and function (Godel et al., 2011; Cina et al., 2012; Jeruschke et al., 2013; Muller-Krebs et al., 2013; Zaza et al., 2014).”
BackgroundInfluentialYou, Y., Huang, X., Chen, H., Lyu, X., Liu, J., & Lan, H. Y. (2016) · Scientific Reports · doi:10.1038/srep26740 · Cited by 79
“Emerging evidence shows that activation of mTOR plays a pivotal role in many kidney diseases including mesangial expansion, glomerular basement membrane thickening and tubulointerstitial fibrosis in diabetic nephropathy 14,15,36–41 .”
mTOR Signaling in Autophagy Regulation in the Kidney
Inoki, K. (2014) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2013.11.002 · Cited by 69
Self-citationEndoplasmic reticulum stress and kidney dysfunction
Gallazzini, M., & Pallet, N. (2018) · Biology of the Cell · doi:10.1111/boc.201800019 · Cited by 74
Arif, E., Solanki, A. K., Srivastava, P., Rahman, B., Fitzgibbon, W. R., Deng, P., Budisavljevic, M. N., Baicu, C. F., Zile, M. R., Megyesi, J. K., et al. (2019) · Kidney International · doi:10.1016/j.kint.2019.03.023 · Cited by 71
Rozen‐Zvi, B., Hayashida, T., Hubchak, S. C., Hanna, C., Platanias, L. C., & Schnaper, H. W. (2013) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00215.2013 · Cited by 70
Cellular and molecular mechanisms of diabetic glomerulopathy
Gnudi, L. (2012) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs121 · Cited by 76
“Recently, podocyte-specific activation of mTOR has resulted in a DN-like phenotype, while the genetic reduction of mTORC1 activity significantly prevented renal disease in experimental animal models of diabetes [46, 47].”
BackgroundThe complicated role of mitochondria in the podocyte
Gujarati, N. A., Vasquez, J. M., Bogenhagen, D. F., & Mallipattu, S. K. (2020) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00393.2020 · Cited by 73
Therapeutic potential of pro-resolving mediators in diabetic kidney disease
Vartak, T., Godson, C., & Brennan, E. P. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113965 · Cited by 72
Autophagy: Emerging Therapeutic Target for Diabetic Nephropathy
Kume, S., Yamahara, K., Yasuda, M., Maegawa, H., & Koya, D. (2013) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2013.11.003 · Cited by 68
Cardiac mTOR complex 2 preserves ventricular function in pressure-overload hypertrophy
Shende, P., Xu, L., Morandi, C., Pentassuglia, L., Heim, P., Lebboukh, S., Berthonneche, C., Pedrazzini, T., Kaufmann, B. A., Hall, M. N., et al. (2015) · Cardiovascular Research · doi:10.1093/cvr/cvv252 · Cited by 69
“Thus, the heart behaves like several other organs from which rictor has been removed without affecting an increase in organ weight, including skeletal muscle,(9,10) adipose tissue,(11) and kidney.(49) We conclude that increased global protein synthesis intrinsic to physiological growth or pathological cardiac hypertro…”
BackgroundSelf-citationmTOR Signaling in Kidney Diseases
Gui, Y., & Dai, C. (2020) · Kidney360 · doi:10.34067/kid.0003782020 · Cited by 74
“Dysregulation of mTOR signaling disrupts renal cell homeostasis and results in kidney diseases, such as acute kidney injury (AKI) [5, 6], kidney fibrosis [7, 8], glomerular disease [9, 10], polycystic kidney disease (PKD) [11, 12], and renal cancer [13].”
BackgroundInfluentialResearch progress on multiple cell death pathways of podocytes in diabetic kidney disease
Yang, C., Zhang, Z., Liu, J., Chen, P., Li, J., Shu, H., Chu, Y., & Li, L. (2023) · Molecular Medicine · doi:10.1186/s10020-023-00732-4 · Cited by 73
“Therefore, targeting mTOR-related signaling pathways to improve podocyte autophagy levels is expected to be a promising prospect for DKD therapy (Gödel et al. 2011).”
BackgroundEndoplasmic Reticulum Stress in the Diabetic Kidney, the Good, the Bad and the Ugly
Cunard, R. A. (2015) · Journal of Clinical Medicine · doi:10.3390/jcm4040715 · Cited by 69
“mTORC1 activation in podocytes promotes the development of diabetic nephropathy [138,139] and it is associated with ER stress.”
BackgroundTsai, S.-Y., Rodriguez, A. A., Dastidar, S. G., Del Greco, E., Carr, K. L., Sitzmann, J. M., Academia, E. C., Viray, C. M., Martinez, L. L., Kaplowitz, B. S., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.07.029 · Cited by 63
“Reduced mTORC1 activity has been reported to prevent development of T2D and protect against diabetic nephropathy in both type I and type II diabetic mouse models (Godel et al., 2011; Inoki et al., 2011; Polak et al., 2008; Um et al., 2004; Yang et al., 2007).”
BackgroundZeng, R., Zheng, C., Gu, J., Zhang, H., Xie, L., Xu, L., & Li, E. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12548 · Cited by 68
Wen, D., Tan, R., Zhao, C.-Y., Li, J., Zhong, X., Diao, H., Lin, X., Duan, D. D., Jun-ming, F., Xie, X., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00732 · Cited by 66
Chen, J., Zhao, D., Zhu, M., Zhang, M., Hou, X., Ding, W., Sun, S., Bu, W., Feng, L., Ma, S., et al. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.03.016 · Cited by 65
Role of mTOR Inhibitors in Kidney Disease
Kajiwara, M., & Masuda, S. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17060975 · Cited by 66
“In glomerular disease, short-term activation of mTOR signaling has a positive effect, but long-term activation leads to proteinuria and glomerulosclerosis [66].”
BackgroundInfluentialCompensatory renal hypertrophy following nephrectomy: When and how?
Rojas‐Canales, D. M., Li, J. Y. Z., Makuei, L., & Gleadle, J. (2019) · Nephrology · doi:10.1111/nep.13578 · Cited by 64
Insulin signaling: implications for podocyte biology in diabetic kidney disease
Coward, R. J., & Fornoni, A. (2014) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000078 · Cited by 67
“In particular, the AMP-activated protein kinase (AMPK) [61] and the mTOR pathways [62,63] are key direct modulators of podocyte function that can be affected by intracellular glucose.”
BackgroundSelf-citationZhuang, A., & Forbes, J. M. (2014) · Journal of Endocrinology · doi:10.1530/joe-13-0517 · Cited by 64
“Indeed, despite the fact that hyper-activation of mTORC1 in mouse podocytes led to a phenotype akin to that of DN, reducing mTORC1 activity similarly promoted podocyte dysfunction (Godel et al. 2011), indicating that mTORC1 activity is essential for the development of the podocyte.”
BackgroundmTOR controls kidney epithelia in health and disease
Grahammer, F., Wanner, N., & Huber, T. B. (2014) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft491 · Cited by 61
“Podocyte-specific disruption of the mTORC1 complex resulted in a pathological picture, which clinically most closely resembles secondary focal and segmental glomerulosclerosis (FSGS) with quite stable proteinuria and slow progression [29].”
BackgroundInfluentialSelf-citationRole of Nutrient-Sensing Signals in the Pathogenesis of Diabetic Nephropathy
Kume, S., Koya, D., Uzu, T., & Maegawa, H. (2014) · BioMed Research International · doi:10.1155/2014/315494 · Cited by 60
“Two recent studies using heterozygous-raptor knockout mice revealed that hyperactivation of the mTORC1 signal is strongly associated with the progression of podocyte injury and proteinuria in diabetic animal models [27, 28].”
BackgroundInfluence of autophagy on acute kidney injury in a murine cecal ligation and puncture sepsis model
Sunahara, S., Watanabe, E., Hatano, M., Swanson, P. E., Oami, T., Fujimura, L., Teratake, Y., Shimazui, T., Lee, C., & Oda, S. (2018) · Scientific Reports · doi:10.1038/s41598-018-19350-w · Cited by 66
Chen, Y., Liu, Q., Shan, Z., Mi, W., Zhao, Y., Li, M., Wang, B., Zheng, X., & Feng, W. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01477 · Cited by 64
Cao, H., Luo, J., Zhang, Y., Mao, X., Wen, P., Ding, H., Xu, J., Sun, Q., He, W., Dai, C., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.03.035 · Cited by 65
Crosstalk between glomeruli and tubules
Fogo, A. B., & Harris, R. C. (2024) · Nature Reviews Nephrology · doi:10.1038/s41581-024-00907-0 · Cited by 67
“Of note, mTORC1 increases have been implicated in podocyte injury in diabetes 99,100 , but glomerular cell transcriptional changes were not described in the above human biopsy study 98 .”
Indoxyl Sulfate Contributes to mTORC1-Induced Renal Fibrosis via The OAT/NADPH Oxidase/ROS Pathway
Nakano, T., Watanabe, H., Imafuku, T., Tokumaru, K., Fujita, I., Arimura, N., Maeda, H., Tanaka, M., Matsushita, K., Fukagawa, M., et al. (2021) · Toxins · doi:10.3390/toxins13120909 · Cited by 66
“The activation of mTORC1 (mechanistic target of rapamycin complex 1) in renal tissue was recently reported in renal pathologies such as diabetic kidney disease (DKD) [2], polycystic kidney disease (ADPKD) [3], and focal segmental glomerulosclerosis (FSGS) [4].”
BackgroundEffects of High Glucose and Lipotoxicity on Diabetic Podocytes
Nakamichi, R., Hayashi, K., & Itoh, H. (2021) · Nutrients · doi:10.3390/nu13010241 · Cited by 64
“One of the nutrient-sensing signals is mTORC1, which is upregulated in podocytes and tubular cells in mouse models of diabetes and in patients with DM [22,90].”
BackgroundResearch Progress on the Pathological Mechanisms of Podocytes in Diabetic Nephropathy
Zhang, L., Wen, Z., Han, L., Zheng, Y., Wei, Y., Wang, X., Wang, Q., Fang, X., Zhao, L., & Tong, X. (2020) · Journal of Diabetes Research · doi:10.1155/2020/7504798 · Cited by 72
“[61] found that tightly balanced mTOR activity in podocyte homeostasis is required and suggest that mTOR inhibition can protect podocytes and prevent progressive DN.”
BackgroundYang, L., Liang, B., Li, J., Zhang, X., Chen, H., Sun, J. M., & Zhang, Z. (2021) · Cellular Signalling · doi:10.1016/j.cellsig.2021.110206 · Cited by 64
Peng, L., Chen, Y., Shi, S., & Wen, H. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02696-w · Cited by 62
“The mechanistic target of rapamycin (mTOR) signaling, a key regulator of autophagy, is hyperactivated in DN and plays a pivotal role in the process of podocyte apoptosis and the decreased rate of glomerular filtration [121].”
BackgroundSheng, H., Zhang, D., Zhang, J., Zhang, Y., Lu, Z., Mao, W., Liu, X., & Zhang, L. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.986825 · Cited by 65
mTORC2 critically regulates renal potassium handling
Grahammer, F., Nesterov, V., Ahmed, A., Steinhardt, F., Sandner, L., Arnold, F., Cordts, T., Negrea, S., Bertog, M., Ruegg, M. A., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci80304 · Cited by 58
Self-citationRuby, Gifford, C. C., Pandey, R. P., Raj, V., Sabbisetti, V. S., & Ajay, A. K. (2023) · Cells · doi:10.3390/cells12030412 · Cited by 62
“Studies investigating the activation of mTOR signaling find that short-term treatment of mTOR activation protects podocytes in diabetes mellitus, but long-term activation can lead to proteinuria and progressive glomerulosclerosis [89,98].”
BackgroundAutophagy in Glomerular Health and Disease
Hartleben, B., Wanner, N., & Huber, T. B. (2013) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2013.11.007 · Cited by 60
Self-citationGuzman, J., Jauregui, A. N., Merscher, S., Maiguel, D. A., Muresan, C., Mitrofanova, A. V., Díez-Sampedro, A., Szust, J., Yoo, T., Villarreal, R., et al. (2013) · Diabetes · doi:10.2337/db13-0752 · Cited by 61
“In particular, the AMP-activated protein kinase (AMPK) (17) and the mammalian target of rapamycin (mTOR) pathways (18,19) are key direct modulators of podocyte function that can be affected by intracellular glucose.”
InfluentialSelf-citationMammalian target of rapamycin and the kidney. II. Pathophysiology and therapeutic implications
Lieberthal, W., & Levine, J. S. (2012) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00015.2012 · Cited by 57
“The results of this study suggest that, while the total absence of Raptor abolishes podocyte integrity and function, genetic interventions that reduce the expression of Raptor (and therefore mTORC1 activity) can protect mice from DN (46).”
BackgroundInfluentialBissler, J. J., Budde, K., Sauter, M., Franz, D. N., Zonnenberg, B. A., Frost, M., Белоусова, Е. Д., Berkowitz, N. C., Ridolfi, A., & Kingswood, J. C. (2018) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy132 · Cited by 58
“Preclinical studies have demonstrated that mTORC1 appears to contribute to the development of normal-size glomeruli and podocytes, whereas decreased mTORC1 activity results in glomerular injury [26, 27].”
BackgroundProtective or Harmful: The Dual Roles of Autophagy in Diabetic Retinopathy
Gong, Q., Wang, H., Yu, P., Qian, T., & Xu, X. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.644121 · Cited by 65
Roles of mTOR in Diabetic Kidney Disease
Yasuda‒Yamahara, M., Kume, S., & Maegawa, H. (2021) · Antioxidants · doi:10.3390/antiox10020321 · Cited by 61
“Podocyte-specific Raptor, an essential protein for mTORC1, heterozygous mice with suppressed mTORC1 activity, show reduced urinary proteins in both STZ-induced type 1 diabetic mice [26] and type 2 diabetic db/db mice [27].”
BackgroundRenal mTORC1 activation is associated with disease activity and prognosis in lupus nephritis
Mao, Z., Tan, Y. C. R. S., Tao, J., Li, L., Wang, H., Yu, F., Perl, A., & Zhao, M. (2022) · Rheumatology · doi:10.1093/rheumatology/keac037 · Cited by 61
Diabetes Mellitus in the Transplanted Kidney
Peev, V., Reiser, J., & Alachkar, N. (2014) · Frontiers in Endocrinology · doi:10.3389/fendo.2014.00141 · Cited by 63
“Recent studies suggested that the mTOR pathway of the podocytes plays an important role in the underlying mechanisms of the progression of glomerular diseases (47) and DN (48).”
BackgroundNew targets for treatment of diabetic nephropathy: what we have learned from animal models
Brosius, F. C., & Alpers, C. E. (2012) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e32835b3766 · Cited by 56
Investigations of Glucocorticoid Action in GN
Kuppe, C., van Roeyen, C. R. C., Leuchtle, K., Kabgani, N., Vogt, M., van Zandvoort, M. A. M. J., Smeets, B., Floege, J., Gröne, H., & Moeller, M. J. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016010060 · Cited by 57
Targeting the Pathobiology of Diabetic Kidney Disease
Thomas, M. C. (2021) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2021.07.001 · Cited by 58
Unno, R., Kawabata, T., Taguchi, K., Sugino, T., Hamamoto, S., Ando, R., Okada, A., Kohri, K., Yoshimori, T., & Yasui, T. (2019) · Autophagy · doi:10.1080/15548627.2019.1635382 · Cited by 56
“Kidney stone disease, which occurs in nearly 9% of adults and continues to increase in prevalence worldwide [1,2], is a risk factor for chronic kidney disease (CKD) [3,4] andmay still cause death in the 21st century [5].”
BackgroundAutophagy and mitophagy: physiological implications in kidney inflammation and diseases
Bhatia, D., & Choi, M. E. (2023) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00012.2023 · Cited by 57
Deletion of podocyte STAT3 mitigates the entire spectrum of HIV-1-associated nephropathy
Gu, L., Dai, Y., Xu, J., Mallipattu, S. K., Kaufman, L., Klotman, P. E., He, C., & Chuang, P. Y. (2013) · AIDS · doi:10.1097/qad.0b013e32835f1ea1 · Cited by 52
“This podocin-Cre line is widely used and incomplete Cre-mediated recombination in the podocytes has been reported [20,21].”
BackgroundProgress in Pathogenesis of Proteinuria
Zhang, A., & Huang, S. (2012) · International Journal of Nephrology · doi:10.1155/2012/314251 · Cited by 58
“These results revealed the requirement for tightly balanced mTOR activity in podocyte homeostasis [128].”
BackgroundRelationship between lysosomal dyshomeostasis and progression of diabetic kidney disease
Wu, M., Zhang, M., Zhang, Y., Li, Z., Li, X., Liu, H.-F., Li, X., & Li, X. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04271-w · Cited by 55
The Evolving Importance of Insulin Signaling in Podocyte Health and Disease
Lay, A. C., & Coward, R. J. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00693 · Cited by 54
“In podocytes, signaling via the IR has been shown to influence mTOR activity (22) and, importantly, while regulated mTOR activity is essential for podocyte function, podocyte-specific over-activation of mTORC1 induces podocyte injury and plays an important role in DKD development (42, 43).”
BackgroundAccumulation of α-synuclein mediates podocyte injury in Fabry nephropathy
Braun, F., Abed, A., Sellung, D., Rogg, M., Woidy, M., Eikrem, Ø., Wanner, N., Gambardella, J., Laufer, S. D., Haas, F., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci157782 · Cited by 53
“Glomerular epithelial cells (podocytes) are primary targets in chronic kidney diseases that progress to the requirement of dialysis or transplantation (15–18).”
BackgroundSelf-citationHuang, C., Bruggeman, L. A., Hydo, L. M., & Miller, R. T. (2012) · Experimental Cell Research · doi:10.1016/j.yexcr.2012.03.011 · Cited by 65
“PLD is a primary enzyme in cell signaling to produce phosphatidic acid (PA) which is a critical activator of mammalian target of rapamycin (mTOR) signaling (19–21), a process linked to increase cell mass associated with glomerular hypertrophy (22, 23).”
BackgroundRenal clearance of polymeric nanoparticles by mimicry of glycan surface of viruses
Wyss, P. P., Lamichhane, S. P., Abed, A., Vonwil, D., Kretz, O., Huber, T. B., Sarem, M., & Shastri, V. P. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119643 · Cited by 52
Self-citationModes of podocyte death in diabetic kidney disease: an update
Jiang, A., Song, A., & Zhang, C. (2022) · Journal of Nephrology · doi:10.1007/s40620-022-01269-1 · Cited by 51
“[62] have demonstrated that the mTOR signal is significant for podocyte homeostasis and survival.”
BackgroundWang, H., Misaki, T., Taupin, V., Eguchi, A., Ghosh, P., & Farquhar, M. G. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013090985 · Cited by 52
Metadata
- Authors
- Gödel, M., Hartleben, B., Herbach, N., Liu, S., Zschiedrich, S., Lu, S., Debreczeni-Mór, A., Lindenmeyer, M. T., Rastaldi, M.-P., Hartleben, G., Wiech, T., Fornoni, A., Nelson, R. G., Kretzler, M., Wanke, R., Pavenstädt, H., Kerjaschki, D., Cohen, C. D., Hall, M. N., Rüegg, M. A., Inoki, K., Walz, G., & Huber, T. B.
- Affiliations
- University of Freiburg (DE)
- Ludwig-Maximilians-Universität München (DE)
- University of Zurich (CH)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- Leibniz Institute on Aging - Fritz Lipmann Institute (FLI) (DE)
- University of Miami (US)
- National Institutes of Health (US)
- University of Münster (DE)
- Medical University of Vienna (AT)
- University of Basel (CH)
- Life Sciences Institute (SG)
- Corresponding author
- Huber, Tobias B.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2011-06-01
- Volume
- 121
- Issue
- 6
- Pages
- 2197-2209
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3104746
- OpenAlex
- W2051719011
- Cited by
- 547
- References
- 62
- Citations by year
- 2026: 22 · 2025: 23 · 2024: 28 · 2023: 36 · 2022: 30 · 2021: 43 · 2020: 50 · 2019: 39 · 2018: 40 · 2017: 34 · 2016: 38 · 2015: 36 · 2014: 40 · 2013: 47 · 2012: 25
- FWCI
- 31.77
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- edoc (University of Basel) (acceptedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (122439)
- National Institutes of Health (5r01dk083491-09)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01-DK083491, P30DK081943, DK-083491, R01DK124709)
- Topics
- Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- mTOR, mTORC1, mTORC2, podocytes, diabetic nephropathy, glomerulosclerosis, proteinuria, glomerular hypertrophy, hyperfiltration, mTOR inhibition, glomerular disease, gene deletion
- MeSH terms
- Mechanistic Target of Rapamycin Complex 1, Regulatory-Associated Protein of mTOR, Rapamycin-Insensitive Companion of mTOR Protein, Adult, Animals, Carrier Proteins, Diabetes Mellitus, Experimental, Diabetic Nephropathies, Humans, Kidney Glomerulus, Mice, Inbred C57BL, Mice, Inbred ICR, Mice, Transgenic, Nephrosis, Lipoid, Proteins, Proteinuria, Transcription Factors, Trans-Activators, Mice, Knockout, Disease Progression, Gene Dosage, Genetic Predisposition to Disease, Sirolimus, Multiprotein Complexes, Adaptor Proteins, Signal Transducing, Podocytes, Mice, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.